David Hallal - 04 Jun 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Director
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
04 Jun 2025
Net transactions value
-$671,272
Form type
4
Filing time
06 Jun 2025, 21:03:02 UTC
Previous filing
06 May 2025
Next filing
29 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hallal David Director C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN /s/ Adi Osovsky, as Attorney-in-Fact 06 Jun 2025 0001457477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $164,376 +38,227 $4.30 38,227 04 Jun 2025 Direct F1
transaction ITOS Common Stock Sale $384,946 -38,227 -100% $10.07 0 04 Jun 2025 Direct F1, F2
transaction ITOS Common Stock Options Exercise $164,376 +38,227 $4.30 38,227 05 Jun 2025 Direct F1
transaction ITOS Common Stock Sale $388,004 -38,227 -100% $10.15 0 05 Jun 2025 Direct F1, F3
transaction ITOS Common Stock Options Exercise $164,380 +38,228 $4.30 38,228 06 Jun 2025 Direct F1
transaction ITOS Common Stock Sale $391,455 -38,228 -100% $10.24 0 06 Jun 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -38,227 -33% $0.000000 76,455 04 Jun 2025 Common Stock 38,227 $4.30 Direct F1
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -38,227 -50% $0.000000 38,228 05 Jun 2025 Common Stock 38,227 $4.30 Direct F1
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -38,228 -100% $0.000000 0 06 Jun 2025 Common Stock 38,228 $4.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.